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Abstract: I n t r o d u c t i o n: Acute Kidney Injury (AKI) is a serious early complications in patients with 
acute pancreatitis (AP) that significantly increases mortality rates compared to patients without AKI. The 
early diagnosis of AKI during its treatable phases and implementation of appropriate treatment protocols 
can improve outcomes for this group of patients. A promising biomarker for AKI is neutrophil gelatinase-as-
sociated lipocalin (NGAL). 
A i m: This study evaluated the diagnostic value of NGAL concentrations in serum and in urine for patients 
developing AKI as an early complication of AP compared to AP patients without AKI. Material and meth-
ods: The study group composed of 65 patients (34 men and 31 women) with a mean age of 62.2 ± 16 years 
with AP and hospitalized in the Surgery Department of the Direct Hospital in Sucha Beskidzka, Poland 
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between January and December 2014. Serum NGAL (sNGAL) levels were measured with the BioVendor 
ELISA kit, and urine NGAL (uNGAL) with the Abbott ARCHITECT Analyzer.
R e s u l t s: In the early phase of AP, 11 patients (17%) developed AKI, including 10 patients with stage 1 and 
one with stage 2. AKI was associated with more severe AP, higher BISAP scores, the need for more intensive 
treatment, longer hospital stays and higher mortality. Both serum and urine NGAL concentrations were 
significantly higher in patients with AKI throughout the study and significantly predicted AKI in simple and 
multiple logistic regression adjusted for age, sex and comorbidities. Serum and urine NGAL concentrations 
were significantly correlated with levels of serum urea, creatinine, urine albumin, and the maximum change 
in serum creatinine. Serum and urine NGAL levels also correlated positively with direct neutrophil counts 
and CRP concentrations throughout the study.
C o n c l u s i o n s: The measurement of NGAL levels, particularly in urine, is simple, easy to interpret, rou-
tinely available, and clinically useful in the assessment of dynamic changes in kidney function for patients 
with AP. 
Key words: urine NGAL, severe of acute pancreatitis, acute kidney injury.
Introduction
Acute pancreatitis (AP) in the most of patients have mild course of the disease (MAP — mild 
acute pancreatitis). Laboratory tests and imaging studies performed in the early stages 
of the disease may not give any warning signs of eventual organ failure. But, timely 
recognition of the severity of AP and monitoring of organ function is the only way to 
survive this condition [1–4]. It should be noted that more than half of patients with se-
vere acute pancreatitis (SAP) die within the first week of the illness, and that the most 
common causes of death (70–80%) are acute renal injury (AKI) and acute lung injury 
(ALI) due to acute respiratory distress syndrome (ARDS) [2, 5–9]. The established cri-
teria for measuring AKI, the 2004 RIFLE classification and 2012 KDIGO guidelines, are 
both based on estimated increase in creatinine and decrease in urine output over time 
[8, 10]. These biomarker measurements for AKI were proposed for use internationally 
due to their general availability in clinical settings across the world. Unfortunately, serum 
creatinine level has limited value as an indicator of renal impairment as it varies with 
factors such as muscle mass, age, sex, and diet of the patient [5, 11]. More importantly, 
the increase in serum creatinine usually occurs 24–48 hours after kidney damage [10]. 
As such, monitoring serum creatinine does not meet the diagnostic needs of clinicians 
treating patients with SAP whose condition may change from hour to hour. Similarly, 
the hourly measurement of urine output commonly used in most surgery departments 
is also not an ideal benchmark for estimating renal function. Limitations include general 
variability, invasiveness and laboriousness of acquiring measurements and difficulty of 
interpreting the results. Instead, clinicians need a fast and simple diagnostic tool that 
provides reliable assessment of a patient’s risk for AKI. There is a pressing need for new 
markers of kidney damage that allow for quick diagnosis and appropriate treatment. 
One such promising marker is neutrophil gelatinase-associated lipocalin (NGAL). This 
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protein’s increased concentration in blood serum and urine is observed as early as 4–6 
hours after kidney ischemia or exposure to nephrotoxic agents in both the preclinical 
and reversible phases of AKI [8, 10, 12]. NGAL, also known as gelatinase siderocalin or 
lipocalin 2, is a secretory protein in the lipocalin family present in the granules of neu-
trophils and macrophages [11]. NGAL was first described as a marker for acute kidney 
injury in 2003 when it was found in patients having undergone cardiac surgery [13]. 
Under normal physiological conditions, NGAL is freely filtered by the kidney glomeru-
lus and is mostly resorbed at the proximal convoluted tubule. It begins to be secreted in 
response to kidney ischemia as soon as 2 hours after the injury and may be considered 
as a sort of “renal troponin.” The concentration of NGAL in blood serum is considered 
to be a “morphological” indicator of damage to the renal tubules (as opposed to serum 
creatinine, which is only a marker of kidney activity) [11, 13]. Increased concentration 
of NGAL in urine indicates damage to the proximal convoluted tubule of the nephron 
and lack of resorption. However, the majority of urine NGAL is synthesized in the dis-
tal part of the nephron in response to ischemia or exposure to nephrotoxic agents [10]. 
A clinically negligible expression of NGAL has also been shown in numerous other human 
tissues but only significantly increasing serum NGAL levels in response to inflammatory 
agents. The increase in concentration of urine NGAL during AKI is significantly larger 
than the increase in the serum NGAL.
The aim of the study was to compare the concentrations of NGAL in serum and 
urine for AP patients with AKI and AP patients without AKI at 24, 48 and 72 hours 
after the onset of acute pancreatitis. 
Materials and methods
This prospective observational study included 65 adult patients with a diagnosis of AP, 
treated in the Department of Surgery, District Hospital in Sucha Beskidzka, Poland 
between January and December 2014. AP was diagnosed based on the revised Atlanta 
Classification 2012 [14]. The patients with symptoms of AP lasting longer than 24 hours 
and those who have not signed an informed consent form were excluded from the study. 
The severity of AP was stratified according to the revised Atlanta Classification into 
mild (MAP), moderately severe (MSAP) or severe AP (SAP), based on the presence of 
transient or persistent organ failure, exacerbation of comorbidities and/or local compli-
cations. AKI was diagnosed according to KDIGO guideline, i.e. when serum creatinine 
increased ≥26.5 µmol/L within 48 hours, or ≥1.5-times within 7 days or urine volume 
was <0.5 ml/kg/h for 6 hours [15]. All laboratory tests conducted for the routine assess-
ment of patients were performed in the Department of Laboratory Diagnostics Health 
Care Centre in Sucha Beskidzka on the date of the order. Measured parameters included 
amylase activity, concentration of total calcium, serum albumin, blood urea nitrogen 
(BUN), serum creatinine, C-reactive protein (CRP) and complete blood counts. Complete 
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blood counts were performed on whole blood in K2EDTA using an automated hematol-
ogy counter type 5-diff Sysmex XE 2100 (Sysmex Corp., Japan). Urine NGAL (uNGAL) 
concentration was measured in individual urine samples with an ARCHITECT Ana-
lyzer Abbott Diagnostics (Abbott Park, USA) using chemiluminescent microparticle 
immunoassays (CMIA). Concentration of NGAL in blood serum (sNGAL) was mea-
sured using Human Lipocalin-2/NGAL ELISA kits from BioVendor (Brno. Czech Re-
public) on the Automatic Micro ELISA Reader ELX 808 (BIO-Tek® Instruments Inc., 
Winooski, VT, USA).
The study design was approved by the Bioethics Committee of the Jagiellonian Uni-
versity (Decision No. KBET/247/B/2013).
Statistical analysis
Categorical data were reported as numbers of patients (percentage of the appropriate 
group) and compared with the chi-squared test. Median (lower-upper quartile) or mean 
± standard deviation were reported for continuous variables. The variables’ distribu-
tions were checked for normality using the Shapiro–Wilk’s test. The differences between 
groups were tested with the t-test or Mann–Whitney’s test. Simple correlations between 
NGAL and the selected variables were assessed with the Spearman’s rank coefficient as 
both sNGAL and uNGAL were characterized by non-normal distributions. Odds ratios 
(OR) of 95% with confidence intervals (CI) of 95% were reported in case of the simple 
and multiple logistic regression; multiple models were adjusted for a-priori chosen con-
founders. The results were considered significant at p <0.05. The Statistica 12.5 software 
package (StatSoft, Tulsa, USA) was used for computations.
Results
AP was classified as mild in 46 (71%), moderately-severe in 14 (22%), and severe in 5 (8%). 
At the early phase of AP, 11 patients (17%) developed AKI according to the KDIGO 
criteria. AKI stage 1 was diagnosed in 10 patients and stage 2 in one patient. The clinical 
and laboratory characteristics of patients with and without AKI are reported in Table 
1. The diagnosis of AKI was associated with more severe AP, higher BISAP scores, the 
necessity for more intensive treatment and longer hospital stay, as well as with higher 
mortality (although there were only 3 deaths, all in late phase of the disease) (Table 1). 
Patients with and without AKI did not differ in overall prevalence of comorbidities, 
however, chronic kidney disease and diabetes were significantly associated with AKI 
(Table 1). The comorbidities were observed in nearly 80% of patients, most commonly 
hypertension (22 patients, 34%), ischemic heart disease (18 patients, 28%), and diabetes 
(10 patients, 15%); 7 patients (11%) were diagnosed with lung diseases and 3 (5%) with 
kidney diseases (chronic kidney disease stage G3 in 2 patients and G4 in 4 patients). 
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Table 1. Clinical characteristics of patients with acute pancreatitis (N = 65) and the results of laboratory 
tests at 24 hours.
Variable Patients without AKI (N  =  54)
Patients with AKI  
(N  =  11) p
Male sex, N (%) 27 (50) 7 (63) NS
Age, years 59 ± 18 69 ± 17 NS
Duration of pain until admission, hours 12 (6–24) 16 (8–24) NS
Duration of hospital stay, days 6 (5–8) 14 (10–27) <0.001
Mild acute pancreatitis, N (%) 
Moderately severe acute pancreatitis, N (%)
Severe acute pancreatitis, N (%)
45 (83)
8 (19)
1 (2)
1 (9)
6 (55)
4 (36)
<0.001
BISAP score ≥3 in the first 24 hours, N (%) 0 6 (55) <0.001
Co-morbidities, N (%) 40 (74) 10 (91) NS
Renal disease diagnosed before AP, N (%) 1 (2) 2 (18) 0.020
Diabetes, N (%) 6 (11) 4 (36) 0.034
SIRS, N (%) 2 (4) 6 (55) <0.001
Pancreatic or peripancreatic necrosis, N (%) 1 (2) 2 (18) 0.020
Peripancreatic fluid collections, N (%) 5 (9) 0 NS
Transient organ failure, N (%)* 2 (4) 4 (36) <0.001
Persistent organ failure, N (%)* 1 (2) 4 (36) <0.001
Pleural effusion, N (%) 7 (13) 6 (55) 0.002
Antibiotic prophylaxis, N (%) 21 (40) 10 (91) 0.002
Parenteral nutrition, N (%) 0 3 (27) 0.003
Surgery, N (%) 1 (2) 2 (18) 0.020
Early mortality / late mortality, N (%) 0 / 1 (2) 0 / 2 (18) – / 0.019
Leukocytes, x103/µl 11.2 (9.3–14.6) 13.6 (10.4–18.4) NS
Neutrophils, x103/µl 9.1 (7.4–11.0) 10.7 (6.6–15.6) NS
Hematocrit, % 43.1 ± 4.6 39.4 ± 6.3 NS
Platelets, x103/µl 240 (201–266) 130 (116–230) 0.001
Amylase, U/l 1217 (631–1873) 733 (432–1046) NS
Glucose, mmol/l 7.8 (6.4–10.1) 9.6 (6.6–12.6) NS
Serum albumin, g/l 40.6 (37.7–44.1) 37.6 (29.0–40.0) 0.015
CRP, mg/l 12.2 (2.5–76.8) 128.0 (74.6–225.7) <0.001
Calcium, mmol/l 2.35 (2.21–2.43) 2.18 (1.80–2.39) NS
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Variable Patients without AKI (N  =  54)
Patients with AKI  
(N  =  11) p
Urea, mmol/l 5.9 (4.3–6.9) 11.7 (6.7–15.2) 0.003
Creatinine, µmol/l 73 (63–92) 157 (104–211) <0.001
Urine albumin, mg/dl 340 (150–990) 2300 (560–4650) 0.024
sNGAL, ng/ml 105 (68–137) 276 (229–427) <0.001
uNGAL, ng/ml 26.3 (14.9–43.7) 550.6 (72.6–856.2) <0.001
N — number of patients; BISAP — bedside index for severity in acute pancreatitis; SIRS — systemic inflammatory response 
syndrome; NGAL — neutrophil gelatinase-associated lipocalin; s — serum; u — urine; CRP — C-reactive protein
* according to modified Marshall scoring system.
Fig. 1. NGAL concentrations in serum (sNGAL) and urine (uNGAL) of patients with and without AKI at 
24, 48 and 72 hours after onset of symptoms of AP. Data are shown as median, 25–75 percentile (boxes) and 
non-outlier range (whiskers), points represent the outliers.
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At 24 hours after the onset of AP, the patients who do not developed AKI were 
characterized by higher platelets, decreased in serum albumin, and increased in CRP, 
urea, creatinine as well as higher urine albumin concentrations (Table 1). Serum and 
urine NGAL concentrations were significantly higher in AKI patients throughout the 
study (Table 1, Fig. 1).
In logistic regression analysis, both serum and urine NGAL concentrations signifi-
cantly predicted AKI (Table 2). The association between sNGAL and uNGAL with AKI 
was independent of age, sex and comorbidities. The odds ratios for AKI estimated for 
sNGAL and uNGAL were of similar magnitude.
Table 2. Serum and urine NGAL concentrations as predictors of acute kidney injury in patients with acute 
pancreatitis.
Time* Independent variable Simple OR (95% CI) Adjusted** OR (95% CI)
24 hours
sNGAL, per 10 ng/ml 1.20 (1.08–1.33) 1.09 (1.02–1.18)
uNGAL, per 10 ng/ml 1.20 (1.08–1.35) 1.11 (1.01–1.21)
48 hours
sNGAL, per 10 ng/ml 1.08 (1.02–1.14) 1.07 (1.01–1.14)
uNGAL, per 10 ng/ml 1.08 (1.01–1.15) 1.08 (1.01–1.16)
72 hours
sNGAL, per 10 ng/ml 1.09 (1.02–1.17) 1.19 (1.03–1.38)
uNGAL, per 10 ng/ml 1.10 (1.02–1.18) 1.20 (1.02–1.41)
** Time between the onset of AP symptoms and blood/urine collection for NGAL determination.
** The models were adjusted for age, sex and comorbidities.
Table 3. Simple correlations between serum and urine NGAL concentrations and the selected variables 
during the first 72 hours of acute pancreatitis.
Variable
24 h 48 h 72 h
sNGAL uNGAL sNGAL uNGAL sNGAL uNGAL
Urea R  =  0.34p  =  0.007
R  =  0.21
p  =  0.1NS
R  =  0.25
p  =  0.042
R  =  0.34
p  =  0.008
R  =  0.34
p  =  0.005
R = 0.35
p = 0.005
Creatinine R = 0.40p <0.001
R = 0.16
p = 0.2NS
R = 0.33
p = 0.009
R = 0.32
p = 0.011
R = 0.22
p = 0.08NS
R = 0.11
p = 0.4NS
Creatinine 
max. change* 
R = 0.43
p <0.001
R = 0.45
p <0.001
R = 0.39
p = 0.001
R = 0.38
p = 0.002
R = 0.46
p <0.001
R = 0.39
p = 0.001
Urine albumin R = 0.31p = 0.013
R = 0.51
p <0.001
R = 0.52
p <0.001
R = 0.58
p <0.001
R = 0.11
p = 0.4NS
R = 0.21
p = 0.1NS
CRP R = 0.66p <0.001
R = 0.58
p <0.001
R = 0.70
p <0.001
R = 0.41
p <0.001
R = 0.60
p <0.001
R = 0.53
p <0.001
Neutrophils R = 0.49p <0.001
R = 0.31
p = 0.014
R = 0.71
p <0.001
R = 0.42
p <0.001
R = 0.67
p <0.001
R = 0.57
p <0.001
NGAL — neutrophil gelatinase-associated lipocalin; s — serum; u — urine; CRP — C-reactive protein
* Maximum change in serum creatinine concentrations during the first 72 hours after the onset of symptoms of AP
20
Moreover, both serum and urine NGAL concentrations were significantly correlated 
with other laboratory markers of kidney function, i.e. serum urea, serum creatinine and 
urine albumin (Table 3). Of note, the correlations between NGAL and creatinine con-
centrations were relatively weak or even non-significant in some time-points, however, 
there were significant correlations between both serum and urine NGAL and maximum 
change in serum creatinine, throughout the study (Table 3). Also, both serum and urine 
NGAL were positively correlated with the direct neutrophil counts as well as with CRP 
concentrations (Table 3).
Discussion
The clinical diagnosis of acute pancreatitis requires at least two of the three diagnostic 
criteria: abdominal pain typical to AP, at least a threefold increase of lipase or amylase 
in serum and CT imaging consistent with AP [16]. However, these criteria indicate 
neither the severity nor prognosis of the disease. For these, the clinician needs to con-
duct an experienced analysis of a multitude of additional studies. This requires careful 
clinical observation and continuous monitoring of many parameters such as heart and 
respiratory rates, arterial blood gases, body temperature, pulse oximetry, serum creati-
nine, blood urea nitrogen, level of consciousness on the Glasgow Coma Scale, the pres-
ence of pleural effusion and the presence and extent of pancreatic necrosis as measured 
by Balthazar scoring [3, 17–18]. It should be emphasized that in the case of a patient 
with AP lasting more than 48 hours, organ failure is the major predictor of morbidity 
and mortality regardless of the assessment method of the severity of AP (Ranson Scale, 
APACHE II, BISAP score) [3, 9, 19–21]. The assessment of multiple organ dysfunction 
(Marshall score) is essential for the formulation of a personalized patient treatment plan 
including indications for intravenous fluid administration, enteral and parenteral nutri-
tion, pain management, decompressive nasogastric tube, antibiotics, percutaneous 
drainage, endoscopic treatment or laparotomy [8, 14, 16, 22]. The Marshall score assumes 
a loss of kidney function when serum creatinine is between 168 and 318 mmol/L 
(1.9–3.6 mg/dL), while levels below 124 mmol/L (1.4 mg/dL) indicate normal kidney 
function [23]. This classification is not consistent with the definition of AKI currently 
used by nephrologist. Notably, KDIGO guidelines are based on the change of serum 
creatinine concentration over time as well as hourly urine output [15]. These guidelines 
specify treatment protocols for patients depending on the severity of AKI and can be 
useful in speeding up decision making in time-sensitive cases [15]. In the present study, 
the severity of AKI as defined by KDIGO correlated with a longer hospital stay, sever-
ity of AP, severity of disease as assessed with the BISAP score upon admission, the ad-
vent of systemic inflammatory response syndrome (SIRS), persistent organ failure and 
the presence of pleural effusion. Patients with diagnosed AKI had more frequent need 
for antibiotic administration and surgical intervention. These results are confirmed by 
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the observations of other authors, for whom the presence of AKI indicated a poor prog-
nosis for AP patients [24–25]. But, since evaluating AKI based on serum creatinine and 
urine output can be inadequate, the clinician is in need of a simple biomarker for the 
assessment of patients with AP with special consideration of renal function. The ideal 
biomarker, to be useful clinically, should be easy to measure and interpret, dynamically 
responsive to the patient’s condition and reliable in informing therapeutic decisions. 
Based on previous studies, NGAL concentrations in the serum and urine are excellent 
candidates as clinically useful biomarkers in the evaluation of patients with AP. Patients 
with AKI had significantly higher concentrations of sNGAL and uNGAL compared to 
those that did not develop this complication. Additionally, this study’s results demon-
strate that significantly higher levels of NGAL in serum and urine also correlate with 
a more severe clinical state (e.g. higher BISAP scores in the first 24 hours, greater organ 
dysfunction assessed via Marshall score, accompanying pancreatic necrosis or presence 
of pleural effusion) and higher parameters of inflammation (CRP and direct neutrophil 
count) [Table 1]. Lipinski et al. [2] observed that urine NGAL levels in AP patients, 
particularly when collected in the first 24 hours, is a reliable predictor of more severe 
disease and mortality. In the cited work uNGAL levels above 68.9 ng/mL were predictive 
of SAP [2]. Our clinical observations support this interpretation of uNGAL levels to 
rapidly identify AP patients at risk for AKI, when the samples are taken during the first 
day of hospitalization. The vast majority of patients our study group that developed AKI 
had concentration uNGAL was higher than 100 ng/mL. It can be concluded that these 
patients would benefit from immediate and aggressive prevention of AKI. This should 
primarily include intensive rehydration precisely regulated by the daily urine output, 
blood pressure and blood volume based on daily measurements of body weight. It should 
also include the elimination of potentially nephrotoxic drugs and avoiding the use of 
imaging studies with potentially nephrotoxic contrast agents, at least until the decrease 
in the concentration of uNGAL. These patients also require careful dosage of drugs 
metabolized by the kidney, depending on their degree of function. Measuring uNGAL 
again after 48 hours allows for the evaluation of the effects of treatment of AKI in AP 
patients. A significant decrease in concentration of uNGAL infers a reduction or avoid-
ance of AKI and should be considered as an effective treatment of this complication. As 
such, in the case of avoiding AKI in AP, uNGAL can be thought of as a “renal troponin” 
similarly predictive as its cardiac counterpart. Other studies have also shown that 
uNGAL levels change dynamically over time (in as little as four hours), after the acti-
vation of a nephrotoxic contrast agent. The measurement of urine NGAL levels is sim-
ple, fast, responsive to change, easily added to routine laboratory protocols and provides 
the clinician with diagnostically and therapeutically relevant information. This marker 
has significant potential for practical application in monitoring the kidney function of 
patients with AP. Neyra et al. [26] found that in patients with AKI in intensive care units, 
albuminuria greater than 30 mg/dL on the dipstick test correlates with a potentially 
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worse prognosis in their AKI recovery compared to similar patients with lower albu-
minuria. Those results correspond well with our study’s significant correlations of high 
uNGAL and sNGAL levels with high albuminuria urine samples (all above 150 mg/dL). 
This correspondence indicates that the levels of these biomarkers in patients 24 and 
48 hours after the onset of abdominal pain have predictive value for AKI. Monitoring 
serum NGAL during the subsequent days of AP allows the clinician to expect either 
improvement or systemic inflammation and the development of SIRS (Systemic Inflam-
matory Response Systems). Lipinski et al. [2] observed that the initial phase of SAP is 
marked by the release of NGAL from ischemic cells and organs (particularly the kidney), 
which is typical of the pathophysiology of acute systemic diseases. In our study, mea-
surement of sNGAL at 24, 48 and 72 hours after admission yielded comparably increas-
ing concentrations. This increase should be treated like other acute phase proteins, such 
as increasing CRP or declining serum albumin, that signal a systemic inflammatory 
process developing as part of AP. Although the authors observed a statistically significant 
correlation between the increase of sNGAL in AP patients with AKI compared to AP 
patients without AKI (229–427 ng/mL vs 68–137 ng/mL), it is the levels of uNGAL 
that showed the more remarkable correlations for these two groups of patients 
(72.6–856.2 ng/mL vs. 14.9–43.7 ng/mL) [Table 1]. This conclusion is supported by the 
study authored by Soto et al. [27] based on prospective observation of 616 ICU patients, 
confirming the usefulness of sNGAL levels in the monitoring of renal function in pa-
tients with AKI [27]. Measurements of NGAL in the urine and serum, however, have 
its limitations. Because it is a protein associated with neutrophil gelatinase, the in- 
crease in NGAL levels can be a consequence of the presence of an infection in the body 
which may not necessarily be associated with AP (eg. bacterial pneumonia or pyelone-
phritis) [28]. There is also evidence that sNGAL levels increase in patients with pancre-
atic cancer, and although it is not a very specific marker for this disease, this protein 
may be present in the early stages of tumor development [29]. It is also reported that 
concentration of sNGAL may increase in cancers of other organs including 
the ovaries, lungs and stomach [30–32]. Increases in uNGAL are in turn observed in 
patients with chronic renal failure even in the very early stages [33], and in patients 
with leukocyturia, which may limit the predictive quality of the biomarker in the as-
sessment of renal failure in patients with AP. These limitations require further study 
to validate.
Conclusions
Acute pancreatitis is a complex disease that if accompanied by organ failure can cause 
serious complications and death. Measuring NGAL levels, particularly in urine, in patients 
with AP is simple, easy to interpret, routinely available and above all clinically useful 
in the diagnosis and evaluation of dynamic changes in renal function. NGAL levels in 
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these patients is correlated with other parameters of inflammation and is most useful 
as an additional test in the assessment of ongoing systemic inflammation. These results 
need further research on larger groups of patients to be fully validated.
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